Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.
Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, Chiofalo MG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A. Faggiano A, et al. Among authors: severino r. Endocrine. 2018 Oct;62(1):46-56. doi: 10.1007/s12020-018-1583-7. Epub 2018 Mar 23. Endocrine. 2018. PMID: 29572709
A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal.
Faggiano A, Milone F, Ramundo V, Chiofalo MG, Ventre I, Giannattasio R, Severino R, Lombardi G, Colao A, Pezzullo L. Faggiano A, et al. Among authors: severino r. J Clin Endocrinol Metab. 2010 Sep;95(9):E32-6. doi: 10.1210/jc.2010-0045. Epub 2010 Jun 9. J Clin Endocrinol Metab. 2010. PMID: 20534767 Clinical Trial.
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.
Faggiano A, Ramundo V, Dicitore A, Castiglioni S, Borghi MO, Severino R, Ferolla P, Crinò L, Abbruzzese A, Sperlongano P, Caraglia M, Ferone D, Hofland L, Colao A, Vitale G. Faggiano A, et al. Among authors: severino r. J Cell Mol Med. 2012 Jul;16(7):1563-72. doi: 10.1111/j.1582-4934.2011.01438.x. J Cell Mol Med. 2012. PMID: 21883896 Free PMC article.
Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels.
Milone F, Ramundo V, Chiofalo MG, Severino R, Paciolla I, Pezzullo L, Lombardi G, Colao A, Faggiano A. Milone F, et al. Among authors: severino r. Clin Endocrinol (Oxf). 2010 Jul;73(1):85-8. doi: 10.1111/j.1365-2265.2009.03759.x. Epub 2009 Dec 18. Clin Endocrinol (Oxf). 2010. PMID: 20039894
Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses.
Ferolla P, Faggiano A, Grimaldi F, Ferone D, Scarpelli G, Ramundo V, Severino R, Bellucci MC, Camera LM, Lombardi G, Angeletti G, Colao A. Ferolla P, et al. Among authors: severino r. J Endocrinol Invest. 2012 Mar;35(3):326-31. doi: 10.3275/7869. Epub 2011 Jul 13. J Endocrinol Invest. 2012. PMID: 21757992 Clinical Trial.
127 results